Last reviewed · How we verify
NCT03477331: OptimAT
Antithrombotics' Therapeutic Optimization in Hospitalized Patients Using Physiologically- and Population-based Pharmacokinetic Modeling
trial in Cardiovascular Diseases in 444 participants. Completed in 31 January 2024.
31 January 2024
Quick facts
| Lead sponsor | University Hospital, Geneva |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 444 |
| Start date | 14 January 2018 |
| Primary completion | 31 January 2024 |
| Estimated completion | 31 January 2024 |
| Sites | 1 location across Switzerland |
Conditions studied
- Cardiovascular Diseases — all drugs for Cardiovascular Diseases →
Sponsor
University Hospital, Geneva
Who can join
18 and older, any sex, with Cardiovascular Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main goal of the OptimAT study main goal is to validate a PBPK model for 3 direct oral anticoagulants (rivaroxaban, apixaban, dabigatran) and 3 P2Y12 inhibitors (clopidogrel, ticagrelor, prasugrel) in hospitalized patients.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Liquid Biopsy for Patient Characterization in Cardiovascular Disease: Verification against Markers of Cytochrome P450 and P-Glycoprotein Activities.
Achour B, Gosselin P, Terrier J, Gloor Y, et al · · 2022 · cited 27× · PMID 35262906 · DOI 10.1002/cpt.2576 -
Apixaban and rivaroxaban's physiologically-based pharmacokinetic model validation in hospitalized patients: A first step for larger use of a priori modeling approach at bed side.
Terrier J, Gaspar F, Gosselin P, Raboud O, et al · · 2023 · cited 7× · PMID 37794718 · DOI 10.1002/psp4.13036 -
Population pharmacokinetics of apixaban in a real-life hospitalized population from the OptimAT study.
Gaspar F, Terrier J, Favre S, Gosselin P, et al · · 2023 · cited 6× · PMID 37723920 · DOI 10.1002/psp4.13032 -
Virtual twin approach using physiologically based pharmacokinetic modelling in hospitalized patients treated with apixaban or rivaroxaban.
Gaspar F, Terrier J, Jacot-Descombes C, Gosselin P, et al · · 2025 · cited 3× · PMID 40035306 · DOI 10.1002/bcp.70032 -
Improving Understanding of Fexofenadine Pharmacokinetics to Assess Pgp Phenotypic Activity in Older Adult Patients Using Population Pharmacokinetic Modeling.
Gaspar F, Jacost-Descombes C, Gosselin P, Reny JL, et al · · 2025 · cited 2× · PMID 39798016 · DOI 10.1007/s40262-024-01470-4 -
Relevance and limitations of clinical follow-up in a pharmacokinetic study on direct oral anticoagulants.
Terrier J, Gosselin P, Combescure C, Fontana P, et al · · 2026 · PMID 41847138 · DOI 10.3389/fphar.2026.1761151
Verify or expand the search:
- PubMed search for NCT03477331
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cardiovascular Diseases
Currently open trials in the same condition.
- NCT07442578 — Impact of Exercise Intensity on Cardiac Health in Young Adult Survivors of Childhood Cancer: The PULSE Trial · NA · active not recruiting
- NCT07426263 — Effectiveness of a Therapeutic Education Program on Female Sexuality in Women Attending Cardiac Rehabilitation. · NA · active not recruiting
- NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
- NCT07324278 — Hybrid Stroke Rehab With Mirror Priming · NA · recruiting
- NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting
Other University Hospital, Geneva trials
Trials by the same sponsor.
- NCT07506356 — Investigation of Gastric Emptying by Gastric Ultrasonography in Diabetic Patients Treated With GLP-1 Receptors · recruiting
- NCT07267624 — EARLY Antibiotics aDAptation in Severe Pneumonia(The EARLY ADAPT Study) · NA · not yet recruiting
- NCT06710210 — Hybrid Percutaneous Coronary Intervention Combining a Bioresorbable Scaffold With Drug-coated Balloons Versus a Conventi · NA · not yet recruiting
- NCT07173348 — Hypnosis on Breathlessness Mastery in Patients With Persistent Dyspnea · NA · not yet recruiting
- NCT07129655 — Cholangitis Definition and Treatment After Kasai Hepatoportoenterostomy for Biliary Atresia: TRACK-BA Study (TRacking Ch · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03477331 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Geneva
- Last refreshed: 10 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03477331.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing